Pretreatment Soluble Siglec-5 Protein Predicts Early Progression and R-Chop Efficacy in Diffuse Large B-Cell Lymphoma
Biomarkers in Medicine · 2023
DOI: 10.2217/bmm-2022-0764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomarkers in Medicine, 2023. Verfasst von Xiaoqing Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit(ICU), State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR …. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
To explore the clinical association between soluble Siglec-5/CD163 and clinical feature and prognosis in peripheral blood samples of patients with diffuse large B-cell lymphoma.
Method
Significantly elevated cytokines in peripheral blood were characterized by cytokines array and validated by ELISA.
Results
Compared with CD163, Siglec-5 exhibited superiority in discriminating patients into low- and high-risk subgroups based on overall survival and progression-free survival. In addition, Siglec-5 was an indicator of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) treatment efficacy.
Conclusion
Siglec-5 may be applied as a reliable independent immune indicator for overall survival and progression-free survival. It may also predict R-CHOP efficacy in diffuse large B-cell lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Intensive Care Unit(ICU), State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
- Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
ORCID-Profile: Zhiming Li, Jiajia Huang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, X., Cao, J., Sun, P., Yang, H., Li, H., Ma, W., Wu, X., He, X., Li, J., Li, Z., & Huang, J. (2023). Pretreatment Soluble Siglec-5 Protein Predicts Early Progression and R-Chop Efficacy in Diffuse Large B-Cell Lymphoma. Biomarkers in Medicine. https://doi.org/10.2217/bmm-2022-0764
Vancouver
Sun X, Cao J, Sun P, Yang H, Li H, Ma W, et al. Pretreatment Soluble Siglec-5 Protein Predicts Early Progression and R-Chop Efficacy in Diffuse Large B-Cell Lymphoma. Biomarkers in Medicine. 2023. doi:10.2217/bmm-2022-0764
BibTeX
@article{Sun2023,
author = {Sun, Xiaoqing and Cao, Jianghua and Sun, Peng and Yang, Hang and Li, Huan and Ma, Wenjuan and Wu, Xianqiu and He, Xiaohua and Li, Jing and Li, Zhiming and Huang, Jiajia},
title = {Pretreatment Soluble Siglec-5 Protein Predicts Early Progression and R-Chop Efficacy in Diffuse Large B-Cell Lymphoma},
journal = {Biomarkers in Medicine},
year = {2023},
doi = {10.2217/bmm-2022-0764}
}
EUVIMED